AR090339A1 - Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica - Google Patents
Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopaticaInfo
- Publication number
- AR090339A1 AR090339A1 ARP130100827A ARP130100827A AR090339A1 AR 090339 A1 AR090339 A1 AR 090339A1 AR P130100827 A ARP130100827 A AR P130100827A AR P130100827 A ARP130100827 A AR P130100827A AR 090339 A1 AR090339 A1 AR 090339A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- pulmonary fibrosis
- forecast
- diagnosis
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Se proporcionan composiciones, kits y métodos para confirmar el pronóstico de fibrosis pulmonar idiopática en pacientes. Asimismo, se proporcionan composiciones, kits y métodos para diagnosticar subtipos de fibrosis pulmonar idiopática. También se proporcionan métodos para tratar la fibrosis pulmonar idiopática.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616394P | 2012-03-27 | 2012-03-27 | |
US201261707411P | 2012-09-28 | 2012-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090339A1 true AR090339A1 (es) | 2014-11-05 |
Family
ID=49261043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100827A AR090339A1 (es) | 2012-03-27 | 2013-03-14 | Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica |
Country Status (16)
Country | Link |
---|---|
US (2) | US20160230226A1 (es) |
EP (2) | EP2831280B1 (es) |
JP (1) | JP6404208B2 (es) |
KR (1) | KR102197524B1 (es) |
CN (2) | CN104334744A (es) |
AR (1) | AR090339A1 (es) |
AU (2) | AU2013240344A1 (es) |
BR (1) | BR112014023348A2 (es) |
CA (1) | CA2864884A1 (es) |
HK (1) | HK1206796A1 (es) |
IL (1) | IL256396A (es) |
MX (2) | MX370486B (es) |
NZ (1) | NZ628458A (es) |
RU (1) | RU2014139546A (es) |
SG (2) | SG11201405830VA (es) |
WO (1) | WO2013148232A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2754672B1 (en) | 2011-09-06 | 2019-02-27 | Shino-Test Corporation | Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same |
SG11201603127WA (en) * | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
JP6312054B2 (ja) * | 2013-11-06 | 2018-04-18 | 学校法人日本大学 | 間質性肺炎のバイオマーカー |
US20160256485A1 (en) * | 2013-11-14 | 2016-09-08 | Proterris, Inc. | Treatment or prevention of pulmonary conditions with carbon monoxide |
AU2014386209B2 (en) | 2013-12-20 | 2021-03-11 | President And Fellows Of Harvard College | Low shear microfluidic devices and methods of use and manufacturing thereof |
WO2015120257A2 (en) * | 2014-02-06 | 2015-08-13 | The Brigham And Women's Hospital, Inc. | Uses of gli1 in detecting tissue fibrosis |
TW201618795A (zh) | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | 用以改良器官功能及延長器官移植物壽命之系統及方法 |
WO2015164716A1 (en) * | 2014-04-25 | 2015-10-29 | Brown University | Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome |
US9913819B2 (en) | 2014-06-12 | 2018-03-13 | Yale University | Methods of treating or preventing fibrotic lung diseases |
EP2957634A1 (en) | 2014-06-20 | 2015-12-23 | Consejo Superior De Investigaciones Científicas | Compounds for prevention and/or treatment of fibrotic diseases |
CN114606309A (zh) * | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
CN104792998B (zh) * | 2015-03-09 | 2016-06-08 | 中国人民解放军第四军医大学 | Loxl2抗原用于制备甲状腺癌预示、侵袭、转移试剂盒的应用 |
CN111718413A (zh) * | 2015-06-26 | 2020-09-29 | 上海市肿瘤研究所 | Cthrc1在肝硬化诊断和治疗中的应用 |
WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
CN116077489A (zh) * | 2015-10-27 | 2023-05-09 | 台北医学大学 | 用于治疗及/或预防纤维化疾病的吲哚啉衍生物 |
CN105400870B (zh) * | 2015-11-11 | 2018-09-25 | 南方医科大学 | CD1c在菌阴肺结核诊断中的应用 |
EP3380520A2 (en) * | 2015-11-23 | 2018-10-03 | Merck Patent GmbH | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
US20190144547A1 (en) * | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
EP3464240A1 (en) * | 2016-05-27 | 2019-04-10 | Boehringer Ingelheim International GmbH | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
CN106319058B (zh) * | 2016-08-31 | 2019-09-10 | 汪道文 | 一种检测特发性肺纤维化致病基因的dna文库及其应用 |
AU2017324949A1 (en) * | 2016-09-07 | 2019-02-28 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
US11397178B2 (en) | 2016-10-28 | 2022-07-26 | Cedars-Sinai Medical Center | Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy |
US20200017913A1 (en) * | 2017-03-02 | 2020-01-16 | President And Fellows Of Harvard College | Methods and systems for predicting treatment responses in subjects |
IT201700026858A1 (it) * | 2017-03-10 | 2018-09-10 | Univ Degli Studi Padova | Uso di inibitori delle serin proteasi, in particolare di serpinb3 |
US20190127456A1 (en) * | 2017-10-31 | 2019-05-02 | Fibrogen, Inc. | Methods of treating idiopathic pulmonary fibrosis |
CN108931645A (zh) * | 2018-07-26 | 2018-12-04 | 北京大学第医院 | 一种hcv清除后肝纤维化评估系统及评估方法 |
EP3849580A4 (en) | 2018-09-10 | 2022-06-15 | Lung Therapeutics, Inc. | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THEIR USE IN THE TREATMENT OF FIBROSIS |
CN112969921A (zh) | 2018-10-29 | 2021-06-15 | 国立大学法人东京医科齿科大学 | 取得间质性肺炎患者的呼吸功能的降低风险相关信息的方法及其利用 |
US20220291231A1 (en) * | 2019-01-11 | 2022-09-15 | University Of Virginia Patent Foundation | Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis |
ES2957479A1 (es) * | 2022-06-07 | 2024-01-19 | Baigene S L | Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis |
CN115925920B (zh) * | 2022-08-04 | 2023-07-25 | 瑞因细胞工程科技(广州)有限公司 | 一种基因增强型免疫细胞治疗肝硬化的方法 |
CN117747093A (zh) * | 2024-02-20 | 2024-03-22 | 神州医疗科技股份有限公司 | 一种特发性肺纤维化诊断模型的构建方法及诊断系统 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
EP0598877B1 (en) | 1992-06-09 | 1999-07-28 | Hoppe Ag | Latch and lockset system |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
AR045614A1 (es) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
PT2805728T (pt) * | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
WO2006124451A2 (en) | 2005-05-11 | 2006-11-23 | Centocor, Inc. | Anti-il-13 antibodies, compositions, methods and uses |
CA2623429C (en) | 2005-09-30 | 2015-01-13 | Medimmune Limited | Interleukin-13 antibody composition |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
BRPI0706575B8 (pt) * | 2006-01-13 | 2021-05-25 | Univ Indiana Res & Tech Corp | uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado. |
TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之c-kit抗體 |
EP2068920A2 (en) * | 2006-10-05 | 2009-06-17 | Centocor Ortho Biotech, Inc. | Ccr2 antagonists for treatment of fibrosis |
WO2008083695A1 (de) | 2006-12-20 | 2008-07-17 | Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH | Vorrichtung und verfahren zur messung der intensität des lichtes einer ersten gruppe von lichtquellen einer beleuchtungseinheit |
CA2685123A1 (en) * | 2007-04-23 | 2008-10-30 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP2728017B1 (en) * | 2007-11-19 | 2016-08-24 | Celera Corporation | Lung cancer markers and uses thereof |
AU2009231733B2 (en) * | 2008-03-31 | 2015-12-24 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
WO2010028274A1 (en) * | 2008-09-05 | 2010-03-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation |
EP2358754A1 (en) * | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Ligands that bind il-13 |
WO2010141469A2 (en) * | 2009-06-01 | 2010-12-09 | Case Western Reserve University | Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases |
NZ609493A (en) * | 2010-12-16 | 2015-11-27 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
-
2013
- 2013-03-14 WO PCT/US2013/031178 patent/WO2013148232A1/en active Application Filing
- 2013-03-14 EP EP13768451.0A patent/EP2831280B1/en active Active
- 2013-03-14 AR ARP130100827A patent/AR090339A1/es unknown
- 2013-03-14 RU RU2014139546A patent/RU2014139546A/ru not_active Application Discontinuation
- 2013-03-14 CN CN201380027564.8A patent/CN104334744A/zh active Pending
- 2013-03-14 NZ NZ628458A patent/NZ628458A/en not_active IP Right Cessation
- 2013-03-14 CN CN201611178102.8A patent/CN107099581B/zh active Active
- 2013-03-14 JP JP2015503288A patent/JP6404208B2/ja active Active
- 2013-03-14 CA CA2864884A patent/CA2864884A1/en not_active Abandoned
- 2013-03-14 EP EP20153153.0A patent/EP3725892A1/en not_active Withdrawn
- 2013-03-14 SG SG11201405830VA patent/SG11201405830VA/en unknown
- 2013-03-14 AU AU2013240344A patent/AU2013240344A1/en not_active Abandoned
- 2013-03-14 KR KR1020147029554A patent/KR102197524B1/ko active IP Right Grant
- 2013-03-14 SG SG10201702842SA patent/SG10201702842SA/en unknown
- 2013-03-14 BR BR112014023348-9A patent/BR112014023348A2/pt not_active IP Right Cessation
- 2013-03-14 MX MX2014011503A patent/MX370486B/es active IP Right Grant
-
2014
- 2014-09-23 US US14/493,649 patent/US20160230226A1/en not_active Abandoned
- 2014-09-25 MX MX2019015159A patent/MX2019015159A/es unknown
-
2015
- 2015-08-03 HK HK15107420.8A patent/HK1206796A1/xx unknown
-
2017
- 2017-12-18 IL IL256396A patent/IL256396A/en unknown
-
2018
- 2018-03-16 US US15/924,114 patent/US20190062836A1/en not_active Abandoned
- 2018-10-16 AU AU2018250393A patent/AU2018250393A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104334744A (zh) | 2015-02-04 |
EP2831280A4 (en) | 2016-02-24 |
WO2013148232A1 (en) | 2013-10-03 |
KR102197524B1 (ko) | 2020-12-31 |
AU2018250393A1 (en) | 2018-11-08 |
NZ628458A (en) | 2016-11-25 |
CN107099581B (zh) | 2021-07-13 |
EP2831280A1 (en) | 2015-02-04 |
CN107099581A (zh) | 2017-08-29 |
AU2013240344A1 (en) | 2014-09-18 |
SG11201405830VA (en) | 2014-10-30 |
BR112014023348A2 (pt) | 2019-03-19 |
CA2864884A1 (en) | 2013-10-03 |
RU2014139546A (ru) | 2016-05-20 |
MX2019015159A (es) | 2020-02-19 |
HK1206796A1 (en) | 2016-01-15 |
EP2831280B1 (en) | 2020-04-15 |
EP3725892A1 (en) | 2020-10-21 |
SG10201702842SA (en) | 2017-06-29 |
US20160230226A1 (en) | 2016-08-11 |
MX370486B (es) | 2019-12-16 |
JP6404208B2 (ja) | 2018-10-10 |
KR20140143196A (ko) | 2014-12-15 |
JP2015522246A (ja) | 2015-08-06 |
IL256396A (en) | 2018-02-28 |
MX2014011503A (es) | 2014-12-05 |
US20190062836A1 (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090339A1 (es) | Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica | |
LTC3057969I2 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit | |
MX2014006130A (es) | Metodos de diagnostico y tratamiento de la fibrosis pulmonar idiopatica. | |
BR112013022813A2 (pt) | diaminocarbonitrila pirimidinas e diaminocarboxamida substituída, composições das mesmas e métodos de tratamento com as mesmas | |
UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
BR112016030798A8 (pt) | composição de marcação fluorescente, métodos para determinar se um local foi limpo e para avaliar a limpeza de uma superfície, e, kits para determinar se uma superfície foi limpa e para avaliar a limpeza de uma superfície | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
CR20110069A (es) | Agentes de fijacion al receptor notch1 y metodos para el uso de los mismos | |
EA201690280A1 (ru) | Композиции и способы, относящиеся к выделенным эндофитам | |
UY34352A (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
CL2013000238A1 (es) | Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos. | |
EA201391154A3 (ru) | Способы и композиции для нацеливания на адипоциты у млекопитающих | |
CO7020867A2 (es) | Formulaciones de anticuerpo y metodos | |
EA201491303A1 (ru) | Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps | |
AR079889A1 (es) | Antagonistas de wnt y metodos de tratamiento y deteccion | |
BR112014031412A2 (pt) | método de preparação de uma composição, composição e seu uso, e kit. | |
UY34200A (es) | 3-(fluorovinil)pirazoles y su uso | |
TR201911039T4 (tr) | Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler. | |
BR112015032526A2 (pt) | composições anticaspa e métodos de uso das mesmas | |
EA201692518A2 (ru) | Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила | |
PH12014501176A1 (en) | Anticoagulant reversal agents | |
CL2013002006A1 (es) | Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto. | |
EA201490562A1 (ru) | Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов | |
ES2414290R1 (es) | Metodo para el diagnostico y/o pronostico de dano renal agudo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |